Tags

Type your tag names separated by a space and hit enter

[Kidney and bone update : the 5-year history and future of CKD-MBD. Progress in therapy of CKD-MBD with vitamin D receptor activators].
Clin Calcium. 2012 Jul; 22(7):1073-81.CC

Abstract

Reduction in serum 1,25 (OH) (2)D level plays an important role in the pathophysiology of altered bone and mineral metabolism among patients with advanced stages of CKD. The use of vitamin D receptor activators (VDRA) has brought great progress in medical management of CKD-MBD. A number of observational studies have shown that the nonuse of VDRA, and low serum concentrations of 1,25 (OH) (2)D or 25 (OH) D are the predictors of poor clinical outcomes in CKD patients including dialysis patients, raising a possibility that the pleiotropic actions of vitamin D may be systemically involved in the poor survival of patients with CKD-MBD. Randomized controlled trials are needed to clarify whether or not VDRA could be beneficial in the protection of the cardiovascular system and good longevity.

Authors+Show Affiliations

Department of Geriatrics and Vascular Medicine, Osaka City University Graduate School of Medicine, Japan.

Pub Type(s)

English Abstract
Journal Article
Review

Language

jpn

PubMed ID

22750940

Citation

Shoji, Tetsuo. "[Kidney and Bone Update : the 5-year History and Future of CKD-MBD. Progress in Therapy of CKD-MBD With Vitamin D Receptor Activators]." Clinical Calcium, vol. 22, no. 7, 2012, pp. 1073-81.
Shoji T. [Kidney and bone update : the 5-year history and future of CKD-MBD. Progress in therapy of CKD-MBD with vitamin D receptor activators]. Clin Calcium. 2012;22(7):1073-81.
Shoji, T. (2012). [Kidney and bone update : the 5-year history and future of CKD-MBD. Progress in therapy of CKD-MBD with vitamin D receptor activators]. Clinical Calcium, 22(7), 1073-81. https://doi.org/CliCa120710731081
Shoji T. [Kidney and Bone Update : the 5-year History and Future of CKD-MBD. Progress in Therapy of CKD-MBD With Vitamin D Receptor Activators]. Clin Calcium. 2012;22(7):1073-81. PubMed PMID: 22750940.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Kidney and bone update : the 5-year history and future of CKD-MBD. Progress in therapy of CKD-MBD with vitamin D receptor activators]. A1 - Shoji,Tetsuo, PY - 2012/7/4/entrez PY - 2012/7/4/pubmed PY - 2012/12/10/medline SP - 1073 EP - 81 JF - Clinical calcium JO - Clin Calcium VL - 22 IS - 7 N2 - Reduction in serum 1,25 (OH) (2)D level plays an important role in the pathophysiology of altered bone and mineral metabolism among patients with advanced stages of CKD. The use of vitamin D receptor activators (VDRA) has brought great progress in medical management of CKD-MBD. A number of observational studies have shown that the nonuse of VDRA, and low serum concentrations of 1,25 (OH) (2)D or 25 (OH) D are the predictors of poor clinical outcomes in CKD patients including dialysis patients, raising a possibility that the pleiotropic actions of vitamin D may be systemically involved in the poor survival of patients with CKD-MBD. Randomized controlled trials are needed to clarify whether or not VDRA could be beneficial in the protection of the cardiovascular system and good longevity. SN - 0917-5857 UR - https://www.unboundmedicine.com/medline/citation/22750940/[Kidney_and_bone_update_:_the_5_year_history_and_future_of_CKD_MBD__Progress_in_therapy_of_CKD_MBD_with_vitamin_D_receptor_activators]_ L2 - https://medlineplus.gov/minerals.html DB - PRIME DP - Unbound Medicine ER -